New live bacterial product for stubborn superbug improves quality of life Microbiome therapeutic tackles C. diff, the most common health care-associated infectious agent in the US. Date: January 31, ...
C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...
Please provide your email address to receive an email when new articles are posted on . Clostridioides difficile infection presents a unique treatment paradox for clinicians: Antibiotics are often ...
In a phase-one human clinical trial, a pharmacist researcher has demonstrated that a new antibiotic, called Omadacycline, may be a promising tool in combating the superbug known as C diff which causes ...
Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results